VistaGen Therapeutics, Inc.
384 Oyster Point Boulevard
South San Francisco
162 articles with VistaGen Therapeutics, Inc.
Lots of interesting biotech news from Asia, Europe and elsewhere was reported this week. From tapeworms to using a breathalyzer test in lung cancer diagnostics, the global biotech industry is exploding with ideas.
1/16/2019Developing treatments to help those struggling with depression, a disorder that can lead to suicide, has become a mission for Shawn Singh, CEO of VistaGen, and his colleagues.
VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression
VistaGen’s oral NMDA receptor glycine B antagonist in Phase 2 development for adjunctive treatment of major depressive disorder.
VistaGen’s AV-101 Snags Fast Track Designation, Other Drugmakers Move Ahead with Non-Opioid Pain ...
10/6/2018Opioids have shown tremendous efficacy in pain management. At the same time, the dangers of the addiction to the medication have become well-known in recent years as an epidemic has swept across the United States.
VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain
Designation highlights serious unmet need for new treatment options for patients suffering from neuropathic pain
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder
Phase 3-ready asset expands VistaGen’s CNS pipeline and complements its neuropsychiatry focus on Major Depressive Disorder (MDD) with AV-101
There are generally two types of antidepressants on the market. They are selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). But there are still individuals who do not respond well to these drugs and the industry continues to work on developing...
Janssen Pharmaceuticals is eying a potential breakthrough in treating refractory major depressive disorder.
VistaGen Receives Notice Of Allowance From U.S. Patent And Trademark Office For U.S. Patent Regarding Methods Of Production For AV-101
VistaGen Therapeutics, Inc. Appoints Mark A. Mcpartland Vice President Of Corporate Development And Investor Relations
VistaGen Therapeutics, Inc. Appoints Pharmaceutical CNS Drug Development Executive Mark A. Smith M.D., Ph.D. As Chief Medical Officer
VistaGen Therapeutics, Inc. Bolsters Clinical And Regulatory Advisory Board With Appointments Of Distinguished Key Opinion Leaders In Depression
VistaGen Therapeutics, Inc. Secures Exclusive Worldwide Commercial Rights To Three Proprietary Stem Cell Technologies From University Health Network
VistaGen Therapeutics, Inc. Announces First Patient Dosed In NIH-Sponsored Phase 2A Study Of Orally Available AV-101 In Major Depressive Disorder